Rafael (RFL) vs Telomir Pharmaceuticals (TELO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rafael (RFL) has outperformed Telomir Pharmaceuticals (TELO) over the past year, gaining 9.6% versus a loss of 30.3%. Telomir Pharmaceuticals is the larger company by market cap ($84.7 million vs $77.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RFL | TELO |
|---|---|---|
| Share price | $1.48 | $1.15 |
| Market cap | $76.96M | $84.66M |
| 1-day change | 0.00% | +2.68% |
| YTD return | +25.42% | -13.53% |
| 1-year return | +9.63% | -30.30% |
| 5-year return | -95.09% | — |
| EPS (TTM) | $-0.72 | $-1.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.96 | $1.82 |
| 52-week low | $1.12 | $0.888 |
| Distance from 52-week high | -62.63% | -36.71% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +247.83% |
| Average volume | 159.84K | 97.98K |
| Shares outstanding | 51.21M | 73.62M |
| Employees | 21 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RFL has outperformed TELO by 39.9 percentage points over the past year.
About Rafael
RFL stock →Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Telomir Pharmaceuticals
TELO stock →Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.
Health Care · Biotechnology: Pharmaceutical Preparations
RFL vs TELO FAQ
Which is bigger, Rafael or Telomir Pharmaceuticals?
Telomir Pharmaceuticals (TELO) is larger, with a market capitalization of $84.66M compared with $76.96M for Rafael (RFL).
Which stock has performed better over the past year, RFL or TELO?
RFL returned +9.63% over the past 12 months, compared with -30.30% for TELO (price return, excluding dividends). Past performance does not predict future results.
Are Rafael and Telomir Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.